Insider Transactions in Q2 2022 at Nuvectis Pharma, Inc. (NVCT)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 29
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
3,700
+0.12%
|
$40,700
$11.62 P/Share
|
|
Jun 28
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
300
+0.01%
|
$3,300
$11.82 P/Share
|
|
Jun 24
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
400
+0.01%
|
$4,800
$12.18 P/Share
|
|
Jun 23
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
200
+0.01%
|
$2,200
$11.4 P/Share
|
|
Jun 22
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
100
+0.0%
|
$1,300
$13.1 P/Share
|
|
May 27
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.02%
|
$7,500
$15.74 P/Share
|
|
May 26
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
500
+0.02%
|
$7,500
$15.9 P/Share
|
|
May 20
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
300
+0.02%
|
$4,800
$16.54 P/Share
|
|
May 20
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.03%
|
$16,000
$16.28 P/Share
|
|
May 19
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
200
+0.01%
|
$3,600
$18.95 P/Share
|
|
May 18
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
1,700
+0.03%
|
$32,300
$19.55 P/Share
|
|
May 17
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
310
+0.01%
|
$6,200
$20.3 P/Share
|
|
May 17
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
142
+0.01%
|
$2,698
$19.55 P/Share
|
|
May 16
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
100
+0.01%
|
$1,900
$19.28 P/Share
|
|
May 16
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.03%
|
$19,000
$19.32 P/Share
|
|
May 13
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
700
+0.02%
|
$12,600
$18.1 P/Share
|
|
May 12
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
670
+0.03%
|
$10,050
$15.4 P/Share
|
|
May 12
2022
|
Matthew L. Kaplan Director |
BUY
Open market or private purchase
|
Direct |
3,000
+4.1%
|
$48,000
$16.72 P/Share
|
|
May 12
2022
|
Kenneth Hoberman Director |
BUY
Open market or private purchase
|
Direct |
6,000
+9.81%
|
$102,000
$17.4 P/Share
|
|
May 12
2022
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
12,245
+0.14%
|
$195,920
$16.09 P/Share
|
|
May 12
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
1,278
+0.03%
|
$19,170
$15.68 P/Share
|
|
Apr 01
2022
|
Ron Bentsur Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+3.91%
|
-
|
|
Apr 01
2022
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+4.62%
|
-
|
|
Apr 01
2022
|
Enrique Poradosu Chief Science & Business Off |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+4.55%
|
-
|